NEW YORK (GenomeWeb News) — Invitrogen and Progenitor Cell Therapy today said they will co-develop and -market Invitrogen’s media and cell separation technologies, PCT said today.
 
The agreement will include marketing, co-referrals, joint proposals, and technical consulting around Invitrogen’s Dynabeads and Dynabeads ClinExVivo, which are ex vivo T-cell and immune-functioning technologies.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.